SPDR S&P Health Equip

LivaNova Executives to Speak at Goldman Sachs Global Healthcare Conference on June 8

Wolfe Research Lowers Teleflex 2029 Fiscal Year EPS Forecast to $14.19

STAAR Surgical released FY2026 Q1 earnings on May 13 After-Market (EST), actual revenue USD 93.52 M (forecast USD 78.72 M), actual EPS USD 0.1 (forecast USD 0.0285)

Needham Predicts TELA Earnings at $2.90 Per Share for Q1 2028

Wall Street Zen Downgrades Teleflex Stock Rating to Sell

Teleflex Reports Q1 2026 Earnings and Launches Share Repurchase Program

Lantheus released FY2026 Q1 earnings on May 7 Pre-Market (EST), actual revenue USD 377.33 M (forecast USD 354.42 M), actual EPS USD 1.8 (forecast USD 0.9633)

Teleflex released FY2026 Q1 earnings on May 7 Pre-Market (EST), actual revenue USD 548.26 M (forecast USD 537.59 M), actual EPS USD -0.1849 (forecast USD 0.3466)

Livanova released FY2026 Q1 earnings on May 6 Pre-Market (EST), actual revenue USD 362.3 M (forecast USD 346.11 M), actual EPS USD 0.4 (forecast USD 0.6)

Avanos Medical released FY2026 Q1 earnings on May 5 (EST), actual revenue USD 182.2 M (forecast USD 170 M), actual EPS USD 0.1096

STAAR Surgical to Release FY2026 Q1 Earnings on May 13 After-Market EST, Forecast Revenue USD 78.72 M, EPS USD 0.0087

Integra LifeSciences released FY2026 Q1 earnings on May 5 Pre-Market EST, actual revenue USD 391.92 M (forecast USD 381.77 M), actual EPS USD -0.06 (forecast USD 0.05)

Glaukos COO Sold Company Stock

Glaukos releases investor presentation on glaucoma treatment pipeline

Novocure released FY2026 Q1 earnings on April 30 Pre-Market (EST), actual revenue USD 174.06 M (forecast USD 167.77 M), actual EPS USD -0.6231 (forecast USD -0.5128)

Lantheus to Release FY2026 Q1 Earnings on May 7 Pre-Market EST, Forecast Revenue USD 354.38 M, EPS USD 0.95

Teleflex to Release FY2026 Q1 Earnings on May 7 Pre-Market EST, Forecast Revenue USD 537.59 M, EPS USD 0.3466

Glaukos released FY2026 Q1 earnings on April 29 After-Market EST, actual revenue USD 150.57 M (forecast USD 137 M), actual EPS USD -0.3409 (forecast USD -0.38)

Livanova to release FY2026 Q1 earnings report on May 6 Pre-Market EST, forecast revenue USD 346.11 M, EPS USD 0.6

Axogen released FY2026 Q1 earnings on April 28 Pre-Market (EST), actual revenue USD 61.46 M (forecast USD 57.77 M), actual EPS USD -0.38 (forecast USD -0.3857)

InMed Pharmaceuticals

NextNRG

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Meiwu Tech

QUARTZSEA ACQUISITION CORP ORD USD0.0001 (18/02/2030) (S/R)

CN Energy

Generation Income Properties

MetaVia

Pinned News

置顶新闻

Boston Scientific Advances Coronary Calcium Treatment With Positive Trial Results

Boston Scientific announced positive results from the FRACTURE trial for its SEISMIQ 4CE coronary IVL catheter, achieving primary safety and effectiveness goals in severe CAD patients. The trial showed a 93.3% freedom from major adverse cardiac events and a 93.7% procedural success rate. The device aims to improve stent placement by fracturing calcium buildup in arteries. Boston Scientific shares rose 2.27% to $57.19 following the announcement.

benzinga_article

Boston Scientific

iShares US Medical Devices

S&P 500

Stellantis NV

ALGN

Dr. Michael McClain discusses in HelloNation how Invisalign and braces can treat various orthodontic issues, including bite alignment, crowding, and spacing. The article highlights common problems like overbites, crossbites, and open bites, explaining that both treatments can effectively address these concerns. It emphasizes the importance of proper diagnosis and individualized care for optimal outcomes, noting that treatment can begin at different ages and contributes to long-term oral health.

Unusual Whales

Align

Health Care Select Sector SPDR

In HelloNation, Orthodontics Expert Dr. Michael McClain Details What Orthodontic Problems Invisalign and Braces Can Fix

PAVM

Analyst Anthony Vendetti from Maxim Group has reaffirmed a Buy rating on PAVmed, maintaining a price target of $16. He cites the company's expanding oncology platforms, strategic partnerships, and the rollout of the Veris Cancer Care Platform as key factors. Vendetti highlights PAVmed's stake in Lucid Diagnostics and the momentum of EsoGuard testing, along with the relaunch of its medical device portfolio, as supporting elements for his rating.

Tip Ranks

PAVmed

Lucid Diagnostics

Icecure Medical

Daxor

PAVMED INC C/WTS 30/04/2025(TO PUR COM) CLASS Z

Analyst Reaffirms Buy on PAVmed, Citing Oncology Platform Momentum and Partnerships; Price Target Maintained at $16

GEHC

Analysts at Argus have lowered their price target for GE HealthCare Technologies (NASDAQ:GEHC) from $95.00 to $80.00, maintaining a 'buy' rating. Other firms like JPMorgan and Mizuho have also adjusted their targets, with JPMorgan setting it at $65.00. Currently, GEHC's stock trades at $62.05, with an average price target of $80.63 from analysts. The company reported earnings of $0.99 per share, missing estimates, but revenue increased by 7.4% year-over-year.

Market Beat

GE HealthCare Tech

JPMorgan Chase

Mizuho Financial

Mizuho Financial Group, Inc.

BNP Paribas

Evercore

Barclays

GE Aerospace

Honeywell

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Honeywell International - WI

GE HealthCare Technologies (NASDAQ:GEHC) Price Target Cut to $80.00 by Analysts at Argus

SBIO

Nexalin Technology Inc. (NXL) has acquired PONM Inc. from GreenLight Ventures for $1.3 million, enhancing its HALO Clarity program with AI-integrated remote patient monitoring and virtual clinic management tools. This acquisition supports Nexalin's pivotal trial for moderate-to-severe insomnia, expected to begin in Q2 2026. GreenLight Ventures becomes a significant equity holder and strategic partner, aiding in product and regulatory support. Nexalin's stock closed at $0.32, down 5.26%.

nasdaq

Nexalin Tech

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Nasdaq

NEXALIN TECHNOLOGY INC C/WTS 22/09/25(TO PUR COM)

Nexalin Acquires AI Health Platform Ahead Of HALO Clarity Pivotal Trial

513060

On May 19, 2026, the leading sector was the Energy Select Sector SPDR ETF (XLE) with a price change of +0.22%. The Health Care Select Sector SPDR ETF (XLV) also gained slightly. Conversely, the Technology Select Sector SPDR ETF (XLK) led the losses with a decline of -1.95%, followed by the Industrial (XLI) and Consumer Discretionary (XLY) sectors. This data helps traders analyze market trends for better investment decisions.

Bosera Hang Seng Health Care ETF(QDII)

United States Oil Fund LP

Spdr Select Indu

ProShares Ultra Energy

VG Health

SPDR S&P Software

iShares US Oil Equip & Svcs

Ark Genomic Revolution ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

SPDR Energy Select

Pro Ultr Bloomberg Crude Oil

SPDR O&G Ex & Prd

VG Energy

ISHRS S&P Glb Engy

iShares Expanded Tech Software Sector ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

VanEck Oil Services ETF

Spdr Select Tech

SPDR FD Consumer Discretionary

Spdr Material

Real Est Select Spdr

Comm Servcies Select Sector SPDR

Financial Select Sector SPDR Fund

SPDR FD Consumer Staples

Leading And Lagging Sectors For May 19, 2026

AMIX

A revolutionary technology has been developed that allows for minimally invasive transvascular access to nerve targets and tissues. This innovative method enables access through and beyond the lumen wall, providing a less invasive approach for procedures. This breakthrough is set to significantly improve treatment options for patients, with a success rate of over 90% in initial clinical trials. This technology is expected to benefit a wide range of medical fields and has the potential to transform minimally invasive procedures globally.

Autonomix Medical

Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation

HSCS

HeartSciences Inc. has signed a commercial agreement with North Shore Health to deploy its MyoVista Insights™ platform, marking the first hospital deployment within the Cibolo Health network. This SaaS-based agreement aims to enhance ECG management through AI integration, improving workflow efficiency and EHR interoperability. HeartSciences' CEO expressed optimism about further adoption across Cibolo's network of 127 hospitals, while North Shore Health highlighted the platform's potential to modernize cardiac care.

Fidelity

HeartSciences

HEARTSCIENCES INC C/WTS (TO PUR COM)

HeartSciences Signs Commercial Agreement with North Shore Health, the First Hospital Deployment from the Cibolo Health Network

Johnson & Johnson (NYSE: JNJ) is highlighted as a strong investment choice due to its robust business model, AAA credit rating, and a history of 64 consecutive dividend increases. Despite facing legal challenges and potential government price negotiations, the company is expected to grow sales by 7% year-over-year by 2026. Its diversified portfolio and essential products position it well to navigate economic downturns, making it a reliable option for investors seeking stability.

Johnson & Johnson

iShares US Pharma

iShares Global Healthcare

NVIDIA

Intel

S&P Global

NVIDIA Corporation

Meet the Dividend King With a Higher Credit Rating Than the U.S. Government

MTVA

VRAX

In Tuesday's pre-market session, MetaVia (MTVA) shares surged 50.5% to $1.67, while Virax Biolabs (VRAX) rose 38.68% to $0.33. Karyopharm Therapeutics (KPTI) increased by 21.98% to $8.71. Conversely, WORK Medical Tech (WOK) fell 38.1% to $0.24, and Onconetix (ONCO) decreased by 24.77% to $0.23. Several companies reported Q1 earnings recently, impacting stock movements.

WORK Medical Tech

Virax Biolabs

Onconetix

Karyopharm Therap

Invesco Nasdaq Biotechnology ETF

Jasper Therapeutics

Hyperliquid Strategies

Purple Biotech

Sunshine Biopharma

Wellgistics Health

Picard Medical

GeoVax Labs

SUNSHINE BIOPHARMA INC C/WTS (TO PUR COM)

GEOVAX LABS INC C/WTS 29/09/2025(TO PUR COM)

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

ISRG

ISUL

Resona Asset Management Co. Ltd. reduced its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 13.1% in Q4, now holding 212,119 shares valued at $120.6 million. Other hedge funds, like Brighton Jones LLC and Main Street Financial Solutions LLC, increased their stakes. Insider sales included EVP Gary Loeb selling 400 shares and SVP Mark Brosius selling 2,362 shares. Intuitive Surgical's stock opened at $439.92, with a market cap of $155.8 billion and a recent earnings report showing a 23% revenue increase year-over-year.

Intuitive Surgical

GraniteShares 2x Long ISRG Daily ETF

Resona Holdings, Inc.

Truist Financial

Resona Asset Management Co. Ltd. Reduces Stock Holdings in Intuitive Surgical, Inc. $ISRG

SPDR S&P Health Equip(XHE.US)

Boston Scientific Advances Coronary Calcium Treatment With Positive Trial Results

In HelloNation, Orthodontics Expert Dr. Michael McClain Details What Orthodontic Problems Invisalign and Braces Can Fix

Analyst Reaffirms Buy on PAVmed, Citing Oncology Platform Momentum and Partnerships; Price Target Maintained at $16

GE HealthCare Technologies (NASDAQ:GEHC) Price Target Cut to $80.00 by Analysts at Argus

Nexalin Acquires AI Health Platform Ahead Of HALO Clarity Pivotal Trial